ClinicalTrials.gg
Enrolling by invitationNCT07212686Updated Oct 23, 2026

Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension

A Phase 4 interventional study of Angiotensin-II in Vasodilatory Shock, sponsored by Northwell Health. Enrolling by invitation at 2 sites in United States. Open to participants aged 0 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Northwell Health · Phase 4, Interventional, and Treatment

How we know

Updated Oct 23, 2026Start date movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
0 Days to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Shock with a site in United States — 12 open to participants now, 18 under way, 1 of them phase 3. Shock · United States.

Planned enrollment
35th of 49
30 · median 100
Started
2025
with 3 others
Phase 4
9 of 83
6 open now
Primary completion
2030-06
later than 16 of 17 live
Registered
79th of 83
by date

Among the 83 studies in Shock with a site in United States, this one is the 35th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 4, reaches primary completion later than 16 of the 17 other live ones, and was the 79th registered.

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

Browse Shock studies →

Open to participants now

12 of the 83 studies in Shock with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.

This study: 0 Days to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Shock with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are:

  • To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II
  • To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock.

    • The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug.
    • An ultrasound will be performed to look at blood flow through the kidney in the setting of vasodilatory shock.
    • A follow up phone call to check in with the patient will be performed 28 days after enrollment.
03

Conditions studied

  • Vasodilatory Shock

Browse trials for

Keywords

  • Vasodilatory shock
  • Angiotensin II
  • Pediatric Critical Care Medicine
04

Who can participate

Ages eligible
0 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients less than 18 years of age who have received at least 40 mL/kg of crystalloid or colloid equivalent fluid resuscitation for vasodilatory shock
  • Titration of standard of care vasoactive medications for a minimum of 2 hours with persistent hypotension for age, and who require a total sum NE equivalent dose of > 0.1 μg/kg/min for a minimum of 1 hours and a maximum of 24 hours prior to initiation of Angiotensin-II.
  • Indwelling arterial and central venous lines.
  • Parent or legal guardian is willing and able to provide and assist the patient in complying with all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Standing DNR/DNI order
  • Alternative shock diagnosis i.e. cardiogenic shock or post cardiac surgery
  • Cannulated to extracorporeal membrane oxygenation
  • Pre-existing condition confounding outcome determination such as terminal illness
  • Patients diagnosed with acute occlusive coronary syndrome requiring pending intervention.
  • Patients who have a history of asthma or are currently experiencing bronchospasm requiring the use of inhaled bronchodilators and who are not mechanically ventilated.
  • Patients with acute mesenteric ischemia or a history of mesenteric ischemia.
  • Patients with active bleeding AND an anticipated need of multiple transfusions (within 48 hours of Screening).
  • Patients with active bleeding, \< 7 g/dL, or any other condition that would contraindicate serial blood sampling.
  • Patients requiring more than 5 mg/kg daily of hydrocortisone or equivalent medication as a standing dose.
  • Patients with an expected lifespan of \< 12 hours or withdrawal of life support within 24 hours of screening.
  • Patients currently using an angiotensin converting enzyme inhibitor or angiotensin receptor blocker.
  • Patients with a known allergy to mannitol.
  • Patients who are currently participating in another clinical trial.
  • Patients of who are known to be pregnant at the time of screening.
  • Prisoners
  • Patient's with Raynaud phenomenon, systemic sclerosis, or vasospastic disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pediatric patients in vasodilatory shock

    Patients enrolled in the study who meet inclusion criteria will receive Angiotensin-II per the titration protocol.

    Drug: Angiotensin-II

Interventions

  • Angiotensin-II will be given per the titration protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of patients who have improvement in mean arterial pressure or reduction in sum norepinephrine equivalent at Hour 2 after the start of Synthetic Angiotensin-II

    Percentage (%) of patients who have improvement in mean arterial pressure (MAP, mmHg) or reduction in sum norepinephrine (NE) equivalent at Hour 2 after the start of Synthetic Angiotensin-II

    Time frame: From enrollment to Hour 2

Secondary outcomes

  1. Change in MAP

    Change in mean arterial pressure (mmHg) from baseline to 24 hours

    Time frame: From enrollment to 24 hours

  2. Change in systolic blood pressure

    Change in systolic blood pressure (mmHg) from baseline to 24 hours

    Time frame: From enrollment to 24 hours

  3. Change in diastolic blood pressure

    Change in diastolic blood pressure (mmHg) from baseline to 24 hours

    Time frame: From enrollment to 24 hours

  4. Change in concentration of serum lactate

    Change in concentration of serum lactate (mmol/L) from baseline to 2 hours

    Time frame: From enrollment to 24 hours

  5. Change in pSOFA score

    Change in pSOFA score from screening to 24 hours (%)

    Time frame: From enrollment to 24 hours

  6. Change in PRSIM-III score

    Change in PRSIM-III score from screening to 24 hours (%)

    Time frame: From enrollment to 24 hours

  7. Change in total neutrophil count

    Change in total neutrophil count (cells/µL) from the start of Synthetic Angiotensin-II to 24 hours

    Time frame: From enrollment to 24 hours

  8. Change in renal resistive index (%)

    Change in renal resistive index (%) from the start of Synthetic Angiotensin-II to 24 hours after the start of Synthetic Angiotensin-II

    Time frame: From enrollment to 24 hours

Other outcomes

  1. Change in tissue oxygenation over 2 hours

    Change in tissue oxygenation as defined by peripheral oxygen saturation (%) from baseline to 2 hours

    Time frame: From enrollment to Hour 2

  2. Change in tissue oxygenation over 24 hours

    Change in tissue oxygenation as defined by peripheral oxygen saturation (%) from baseline to 24 hours

    Time frame: From enrollment to Hour 24

  3. Change in heart rate

    Change in heart rate (beats per minute) from baseline to 2 hours

    Time frame: From enrollment to Hour 2

  4. Change in sum norepinephrine equivalent dose over 24 hours

    Change in sum norepinephrine equivalent dose (μg/kg/min) from baseline to 24 hours

    Time frame: From enrollment to 24 hours

  5. 28-day all-cause mortality

    28-day all-cause mortality (%)

    Time frame: From enrollment to Day 28

  6. Number of ventilator days

    Number of ventilator days

    Time frame: From enrollment to Day 28

  7. Ventilator free days

    Number of ventilator free days

    Time frame: From enrollment to Day 28

  8. Days on vasoactive support

    Number of days on vasoactive support

    Time frame: From enrollment to Day 28

  9. Change in T cell cell count

    Change in T cell cell count (cells/µL)

    Time frame: From enrollment to Day 28

  10. Change in in serum cytokine levels

    Change in in serum cytokine levels over time (pg/dL)

    Time frame: From enrollment to Day 28

  11. Change in renal resistive index (%) over time

    Change in renal resistive index (%) over time

    Time frame: From enrollment to 28 days

  12. Change in renal blood flow over time

    Change in renal blood flow (mL/min) over time

    Time frame: From enrollment to 28 days

  13. Change in power doppler by point of care ultrasound assessment

    Change in power doppler by point of care ultrasound assessment (AU)

    Time frame: From enrollment to 28 days

07

Study locations

2 sites
  • Cohen Children's Medical Center of Northwell Health
    New Hyde Park, New York 11040, United States
  • Cohen Children's Medical Center
    Queens, New York 11101, United States
08

References and documents

Publications

  • Bailey DM, Chima RS, Tidmarsh GF, Williams MD. Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients. Crit Care Explor. 2019 Aug 15;1(8):e0036. doi: 10.1097/CCE.0000000000000036. eCollection 2019 Aug. PubMed 32166277 ↗
  • Tezel O, Hutson TK, Gist KM, Chima RS, Goldstein SL, Stanski NL. Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series. Crit Care Explor. 2023 Sep 12;5(9):e0978. doi: 10.1097/CCE.0000000000000978. eCollection 2023 Sep. PubMed 37711646 ↗
  • Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hastbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21. PubMed 28528561 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2025 (actual). Primary completion is estimated for Jun 2030, 56 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Oct 8, 2025
StartActual
Oct 28, 2025was Sep 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 9, 2025→Oct 28, 2025
Oct 23, 2026
Sponsor
Todd Sweberg→Northwell Health
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date Sep 9, 2025→Oct 28, 2025
    Sponsor Todd Sweberg→Northwell Health
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07212686
Lead sponsor
Northwell Health
Collaborators
Innoviva Specialty Therapeutics
Responsible party
Todd Sweberg (MD, Northwell Health) — Principal investigator
First posted
Oct 8, 2025
Start date
Oct 28, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Angiotensin II

Start the discussion